IBRX Q4 2025 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+407.0% YoY

Gross Profit

$34M88.9% margin

Operating Income

-$65M-169.0% margin

Net Income

-$62M-161.8% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+19.4%

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$70M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$502M

Total Liabilities

$1.0B

Stockholders' Equity

-$500M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$8M	+407.0%
Gross Profit	$34M	$8M	+350.7%
Operating Income	-$65M	-$69M	+6.8%
Net Income	-$62M	-$59M	-4.7%

Revenue Segments

Product

$38M100%

Product and Service, Other

$13,0000%

Geographic Segments

UNITED STATES

$38M100%

Europe

$16,0000%